Kornimate/medical-research-clean huggingface dataset:
the exploration of ox40 (cd134) expression levels in sarcoma specimens and its clinical application in prognosis determination

Conditions: Sarcoma; Biomarkers; Progression

Summary: this study aims to investigate the expression of ox40 (cd134) in sarcomas and its impact on prognosis, with the goal of identifying novel biomarkers for early resistance detection and optimizing treatment strategies for sarcoma patients. sarcomas are a highly heterogeneous group of malignant tumors, for which current treatment options are often suboptimal in certain patients, and effective biomarkers to guide therapy are lacking. as a t-cell costimulatory receptor, ox40 plays a significant role in immune regulation across various solid tumors and holds promise as a potential therapeutic target. our research team has previously identified high ox40 expression in sarcomas through database analysis and validated the therapeutic efficacy of antibody-drug conjugates targeting ox40 in in vivo experiments using sarcoma cell lines in murine models. this study will evaluate the mrna expression levels of ox40 in tumor tissues from sarcoma patients and assess ox40 protein expression using immunohistochemical staining. by integrating these findings with clinical and pathological data, the study will explore the potential of ox40 expression levels in tumor tissues as biomarkers for predicting treatment response and prognosis in primary bone tumors. the results aim to provide scientific evidence for the clinical application of ox40-targeted therapies and to propose novel therapeutic strategies to improve survival outcomes in sarcoma patients.


Eligibility criteria:
inclusion criteria: * aged 8 years or older. * diagnosed with high-grade osteosarcoma or ewing sarcoma, confirmed through clinical evaluation or histopathological examination. for patients with localized tumors or solitary pulmonary lesions, pathological confirmation is required; for patients with multiple pulmonary metastases, pathological examination is not necessary. * treatment-naïve patients who have not received standard first-line chemotherapy regimens for osteosarcoma or ewing sarcoma.(first-line chemotherapy drugs include high-dose methotrexate, anthracyclines, cisplatin, and ifosfamide. for ewing sarcoma, the standard first-line regimen is vdc followed by ie.) * all other examination indicators suggest that the patient is eligible for standardized chemotherapy and surgical treatment for bone tumors. exclusion criteria: * inability to undergo standardized chemotherapy and surgical treatment for bone tumors at this center. * refusal to adhere to follow-up according to standardized diagnostic and treatment protocols. * any condition that, in the investigator's opinion, may harm the participant or prevent them from meeting or complying with the study requirements.

Keywords: sarcoma ox40 transcriptomics biomarker cd134 prognosis
intraoperative volume management and qt interval

Conditions: Blood Loss, Surgical

Summary: qt interval changes is measured during all phases of the operation. the protocol is focusing at intraoperative bleeding events and is also observing qt interval changes during anesthetic and operative procedures.

prolongation of the qt interval is associated with functional torsade de points, re-entry, and sudden death (see reference). variations of qt-interval caused by changes in the volume status of the patient during an operation remained unclear. qt interval changes will be monitored during the surgery with the focus of the influence of sudden blood loss, volume substitution by crystalloids, blood and blood products. the effect of surgical procedures on the qt-interval (e.g. clamping of kidney artery) will be observed as well as the association of intra-operative qt-interval alterations with postoperative complications.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status classification 2 - 3 * patients after consent exclusion criteria: * children, * pregnant women, * patients not able to consent

Keywords: electrocardiography hemorrhage monitoring, intraoperative
developement of tiptraq home sleep test

Conditions: Obstructive Sleep Apnea

Summary: the clinical study aims to develop and fine-tune the tiptraq system, created by pranaq, for home sleep apnea screening. the system comprises a wearable device and a cloud-based ai for estimating total sleep time (tst) and apnea-hypopnea index (ahi). this open-label, non-randomized study will recruit 240 subjects aged 20 and older from the veteran general hospital, taipei.

sleep breathing disorders (sbd) is a common disorder in the population. however, a lot of patients are not aware of this disease and do not receive proper treatment, which not only impacts their personal health but also causes public disasters. thus, a screening tool to find those patients becomes a critical point-of-care issue. to achieve this goal, a wearable device that is suitable for the screening is needed. the goal of this study is developing and fine-tuning a new sleep screening platform, tiptraq, developed by pranaq. tiptraq is composed of a wearable device designed as a convenient screening device based on the photoplethysmography (ppg) technique and an interpretable artificial intelligent (ai) system that takes the ppg signal recorded by the wearable device as input and outputs and outputs estimated total sleep time (tst) and apnea-hypopnea index (ahi). the study is open-label and non-randomized, planning to recruit 240 subjects. participants will use the tiptraq device alongside a companion mobile app, with data analysis supported by ai technology hosted on a cloud server. the tiptraq device will be worn over fingertip. the primary goal is to assess the robustness of the tiptraq system and fine-tuned the algorithm by comparing its output against the gold standard psg annotations made by sleep experts.

Eligibility criteria:
inclusion criteria: subjects from the age of 20 and older that have an indication for an in-lab psg study. the subject should be able to understand the study and sign the informed consent before being enrolled in the study. during the study period, the subject can withdraw from the study any time. exclusion criteria: subjects with the following medical conditions will be excluded from this study: 1. heart transplant 2. heart failure, new youk heart association (nyha) classification iii or iv 3. chronic opioid medication user devastating severe strokes, with the modified rankin score (mrs)≥4 4. tracheostomy 5. incapable of comprehending and signing the informed consent and questionnaires, including but not limited to subjects with severe alzheimer's, unconscious by head trauma, or of someone with limited mental capacity 6. cannot correctly follow the order to use the tiptraq device
brain perfusion and hemodynamic stability in patients undergoing radiofrequency ablation of ventricular tachycardia

Conditions: Ventricular Tachycardia

Summary: ventricular tachycardia (vt) is a life-threatening, fast heart rhythm that starts in the lower chambers of the heart (the ventricles). this fast heartbeat is caused by abnormal electrical pathways located in the heart tissue. a standard procedure called a catheter ablation has been used for several years to help correct these abnormal pathways and, in some cases, improve or even eliminate the ventricular tachycardia. during a vt ablation it is routine to monitor your vital signs (blood pressure, heart rate, and oxygen saturation in your blood). if you choose to participate in this study we will also monitor your cerebral oximetry, the amount of blood flow and oxygen saturation to your brain during the ablation. by doing this study, we hope to have a better understanding of patients' blood and oxygen flow to their brain during an episode of ventricular tachycardia (vt).


Eligibility criteria:
inclusion criteria: * able to give informed consent * have implantable defibrillator in-situ and are undergoing ablation procedure for ventricular tachycardia exclusion criteria: * patients who have been hypotensive with systolic blood pressure of \< 80mm hg prior to procedure * cerebral event as defined by cerebrovascular accident or transient ischemia attack within six months prior to procedure

Keywords: radiofrequency ablation fast heart rhythm ventricle catheter ablation ablation
therapy for chronic fatigue syndrome: a presumptive mitochondrial disorder

Conditions: Chronic Fatigue Syndrome

Summary: the purpose of this study is to determine whether therapy that has been shown to be beneficial for mitochondrial diseases is also beneficial for chronic fatigue syndrome (cfs) patients. this study is a chart review of previous cfs patients who received daily conditioning exercise, a high protein diet and nutraceutical therapy (ent). prescribed nutraceutical supplements included alpha-lipoic acid, acetyl-l-carnitine, omega-3fatty acids (maxdha), coenzyme q10 (coq10), plus a multivitamin. twelve cfs male and female patients between the ages of 20-70 years will be recruited to participate in this pilot study. subjects will be eligible to participate if they meet the criteria for cfs of the centers for disease control and prevention (cdc). these include persistent, unexplained fatigue for at least 6 months, concurrent with four of the following: impaired memory/concentration, sore throat, new headaches, unrefreshing sleep, muscle pain, multi-joint pain, tender lymph nodes, and post-exertional malaise.

the etiology and pathogenesis of chronic fatigue syndrome (cfs) is poorly understood. although therapies have been proposed, none has been particularly effective. a preceding viral infection is believed to cause mitochondrial dysfunction in genetically susceptible individuals, resulting in overwhelming fatigue, myalgia and brain fuzziness. the purpose of this study was to determine whether therapy that has been shown to be beneficial for mitochondrial diseases is also beneficial for cfs. patients received daily conditioning exercise, a high protein diet and nutraceutical therapy (ent). prescribed nutraceutical supplements incldued alpha-lipoic acid, acetyl-l-carnitine, omega-3fatty acids (maxdha), coenzyme q10 (coq10), plus a multivitamin, which were selected to enhance mitochondrial function and antioxidant action. following the institution of ent, patients had received this therapy for varying lengths of time, ranging from 12 to 40 months.

Eligibility criteria:
inclusion criteria: severe chronic fatigue for 6 or more consecutive months 4 or more of the following 8 symptoms concurrently: * post-exertion malaise lasting more than 24 hours * unrefreshing sleep * significant impairment of short-term memory or concentration * muscle pain * pain in the joints without swelling or redness * headaches of a new type, pattern, or severity * tender lymph nodes in the neck or armpit * a sore throat that is frequent or recurring these symptoms should have persisted or recurred during 6 or more consecutive months of illness and they cannot have first appeared before the fatigue. exclusion criteria: * additional medical illnesses causing chronic fatigue * ongoing exertion

Keywords: chronic fatigue syndrome mitochondrial disorder conditioning exercise nutraceutical supplements high protein diet
acute effect of massage and exercise on muscle tenderness

Conditions: Musculoskeletal Disorders

Summary: many people experience pain, tenderness and soreness of joint and muscles, both in sport and working life. pain killers can provide acute relief of pain, but may not be a feasible solution for all people. here the investigators examine the acute effect of massage and exercise on induced muscle tenderness (delayed onset muscular soreness).


Eligibility criteria:
inclusion criteria: * working age adults exclusion criteria: * blood pressure above 160/100 * disease of the cervical spine

Keywords: doms
phase 1b/2 study of amg 655 with mfolfox6 and bevacizumab for first-line metastatic colorectal cancer

Conditions: Metastatic Colorectal Cancer; Colon Cancer; Colorectal Cancer; Rectal Cancer

Summary: this phase 1/2, multi-center, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of amg 655 when combined with mfolfox6 and bevacizumab compared with mfolfox6 and bevacizumab alone in subjects with previously untreated metastatic colorectal cancer (crc). the clinical benefit of amg 655 in combination with mfolfox6 and bevacizumab will be measured by progression-free survival, objective response rate, time to response, duration of response, and overall survival. this study is also designed to evaluate the safety and tolerability of amg 655 in combination with mfolfox6 and bevacizumab and to evaluate anti-amg 655 antibody formation and the pharmacokinetics of amg 655.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum. * subjects with measurable or unmeasurable disease * eastern cooperative oncology group (ecog) score of 0 or 1 * men or women at least 18 years of age * adequate hematologic, renal, hepatic and coagulation function exclusion criteria: * history or known presence of central nervous system (cns) metastases * prior chemotherapy or other systemic therapy for advanced or metastatic crc * any investigational agent or therapy for advanced or metastatic crc * clinically significant cardiac disease * clinically significant peripheral neuropathy * active inflammatory bowel disease * recent gastrointestinal ulcer or hemorrhage * recent arterial thrombotic event or pulmonary embolus * recent history of clinically significant bleeding, bleeding diathesis, or coagulopathy * recent major surgical procedure or not yet recovered from major surgery

Keywords: colon cancer colorectal cancer rectal cancer amg 655 bevacizumab modified folfox6 mfolfox6 folfox
evaluation of the use of tranexamic acid in tibial osteotomies

Conditions: Monocompartimental Tibiofemoral Osteoarthritis; Osteoarthritis

Summary: a randomised controlled double-blind clinical trial focused on the evaluation of the effectiveness of the tranexamic acid on bleeding, pain and wound complications reduction in tibial osteotomies. all the 84 included patients will be randomized in one of the two arms, will undergo to a tibial osteotomy and then will prospectively evaluate at different follow ups until 60 days post-surgery

tibial osteotomies represents a well-established treatment option for the medial femorotibial knee arthrosis. osteotomy can be performed in minus or in plus, at the latter case with or without interposition of tissue (autologous bone, heterologous bone or bone substitute). even though excessive bleeding is not a frequent complication, the blood loss and formation of subcutaneous haematoma can determinate more post-interventional pain, wound suffering and the risk of infections. tranexamic acid is an antifibrinolytic agent and its use in proximal tibia osteotomies has been retrospectively evaluated in a number of papers, all of which agree on its safety and efficacy in terms of reducing peri-operative bleeding. however, to date there have been no randomised clinical trials demonstrating its superiority in terms of reducing bleeding, subcutaneous haematoma and wound complications in proximal tibia osteotomies. this is a randomised controlled double-blind clinical trial focused on the evaluation of the effectiveness of the tranexamic acid on bleeding , pain and wound complications reduction in tibial osteotomies

Eligibility criteria:
inclusion criteria: 1. male or female patients aged between 18 and 70 years; 2. single-part tibiofemoral osteoarthritis (k-l 1-3), axial deviation \> 5°; 3. surgical indication for corrective osteotomy; 4. isolated osteotomy surgical procedure. exclusion criteria: 1. contraindication criteria for the administration of tranexamic acid, as assessed by the anaesthesia and resuscitation specialist during the pre-operative visit. the following will be considered absolute contraindications: epilepsy, thrombophilia and known allergy to the active substance, severe renal insufficiency and acute venous or arterial thrombosis, while the following will be considered relative contraindications: coronary stents in patients who have discontinued treatment with antiplatelet agents and previous deep vein thrombosis; 2. known pro-thrombotic conditions (coagulation factor mutations, pregnancy status, previous pulmonary thromboembolism); 3. bmi \> 40; 4. incapacitated patients; 5. patients abusing alcoholic beverages, drugs or medication. 6. patients who are pregnant or breastfeeding.

Keywords: tibial osteotomy tranexamic acid
confounding factors in the detection of intracranial hemorrhage with the infrascanner

Conditions: Ischemic Stroke; Brain Tumor; Brain Surgery; Intracranial Hemorrhage; Headache; Head Trauma

Summary: the investigators prospectively want to use the infrascanner in patients with ischemic stroke, patients with brain surgery, patients with brain tumors, patients with intracranial hemorrhage and patients with a normal ct scan of the brain as part of a diagnostic work-up after head trauma or headache to determine to positive and negative predictive value of the infrascanner in these different settings.

infrascanner is a portable device initially designed to detect intracranial hemorrhage in battlefield traumas. infrascanner uses near infrared spectroscopy to measure cerebral blood flow non-invasively. this is achieved by putting the device against the scalp in 4 different areas (frontal, temporal, parietal, occipital) on the left and right side and by comparing both sides.this allows for the detection of intracranial hemorrhages with a volume upwards of 3.5ml and to a depth of 2.5cm. however, little is known about the influence of other intracranial conditions that could confound the measurements of the infrascanner (e.g. ischemic stroke, brain surgery, brain tumors,...). therefore, the investigators prospectively want to use the infrascanner in patients with ischemic stroke, patients with brain surgery, patients with brain tumors, patients with intracranial hemorrhage and patients with a normal ct scan of the brain as part of a diagnostic work-up after head trauma or headache to determine the positive and negative predictive value of the infrascanner in these different settings.

Eligibility criteria:
inclusion criteria: * patients with ischemic stroke diagnosed by clinical examination and ct-scan * patients with a brain tumor diagnosed by clinical examination and ct-scan or mri * patients with an intracranial hemorrhage diagnosed by clinical examination and ct-scan * patients that have undergone brain surgery * patients with a normal ct-scan of the brain after head trauma * patients with headache complaints and a normal ct-scan of the brain as part of their diagnostic work-up exclusion criteria: * none

Keywords: infrascanner intracranial hemorrhage
treatment of type-1 hepatorenal syndrome associated with sepsis

Conditions: Hepatorenal Syndrome

Summary: type 1 hepatorenal syndrome (type-1 hrs) is a severe complication of patients with advanced cirrhosis characterized by marked renal failure and is associated with a very poor prognosis. type-1 hrs is often precipitated by a bacterial infection, though it may occur spontaneously. it has been demonstrated that vasoconstrictor agents plus albumin are effective in the reversal of the renal failure. a large number of studies have shown that terlipressin improves renal function in patients with type 1 hrs; treatment is effective in 50-75% of patients approximately. currently there are no specific studies about the treatment of type-1 hrs with ongoing infections.

all consecutive patients with cirrhosis hospitalized with an infection or who developed an infection during hospitalization for an acute decompensation of the disease in four university hospitals. criteria for inclusion were: 1/ cirrhosis as diagnosed by liver biopsy or a combination of clinical, biochemical, ultrasonographic, and/or endoscopic findings; 2/ age between 18 and 80 years; 3/ presence of sepsis, as defined by infection and signs of systemic inflammatory response syndrome; and 4/ occurrence of type-1 hrs during the infection, as defined by standard diagnostic criteria. exclusion criteria were: 1/ hepatocellular carcinoma outside the milan criteria; 2/ any severe extrahepatic condition, including cardiovascular, neurological, and organic kidney diseases; 3/ septic or hypovolemic shock; 4/ terminal condition (death expected in less than 48 hours); and 5/ lack of informed consent. aim: a proof of concept study to evaluate whether treatment with terlipressin and albumin in the course of an infection associated with type-1 hrs is effective and safe.

Eligibility criteria:
inclusion criteria: * cirrhosis as diagnosed by liver biopsy or a combination of clinical, biochemical, ultrasonographic, and/or endoscopic findings. * age between 18 and 85 years. * presence of sepsis, as defined by active infection, and signs of systemic inflammatory response syndrome. * occurrence of type-1 hrs during the infection, as defined by standard diagnostic criteria. exclusion criteria: * hepatocellular carcinoma outside the milan criteria. * any severe extrahepatic condition, including cardiovascular, neurological, and organic kidney diseases. * septic or hypovolemic shock. * terminal condition (death expected in less than 48 hours). * lack of informed consent.

Keywords: type-1 hrs active bacterial infections terlipressin and albumin kidney function
effect of clove oil and menthol lozenges on post-extubation sore throat

Conditions: Sore Throat

Summary: in patients undergoing surgical intervention, endotracheal intubation, which is a part of the anesthesia procedure, can cause postoperative sore throat in patients. this situation causes difficulty in swallowing, inadequate nutrition and fluid intake, and prolongs the recovery process. in addition, sore throat is defined as a source of physical stress, which can lead to an increase in the incidence of postoperative morbidity and a decrease in patient satisfaction. this study aimed to investigate the effect of menthol and clove oil lozenges on sore throat after surgery. our aim was to provide evidence on the effectiveness of simple, low-cost menthol and clove oil lozenges in reducing sore throat after extubation, thus helping the patient recover.

this study aimed to investigate the effect of menthol and clove oil lozenges on sore throat in patients after surgery.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65. having had abdominal surgery. being extubated within the first 8 hours after surgery. asa class i-iii. mallampati class i-ii. glasgow coma scale (gcs) score 15 exclusion criteria: * history of allergies. * severe nausea and vomiting. * being extubated after the first 8 hours after surgery. * communication disorders * mallampati class iii-iv. * glasgow coma scale (gcs) score \<15

Keywords: sore throat lozenge postoperative